Assessment cycle 2024 Q1 — page 3
Documents ratified in the 2024 Q1 assessment cycle, which ran from 1 January 2024 to 31 March 2024 and was ratified on 18 March 2024.
Documents ratified
-
Randomised, double-blind, placebo-controlled, phase 2 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low22 Feb 2025 -
Single-arm open-label study of Thymalin in immune modulation over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low10 Sep 2024 -
Randomised, double-blind, placebo-controlled study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low01 Jan 2025 -
Phase 1 ascending dose, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low30 May 2024 -
Randomised, double-blind, placebo-controlled study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low16 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low17 Jul 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Oct 2024 -
Single-arm open-label, phase 3 study of Tirzepatide in hfpef and obesity over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low08 Feb 2025 -
Observational, phase 2 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low10 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low01 May 2024 -
Randomised, double-blind, placebo-controlled, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low06 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low13 Apr 2025 -
Observational study of Thymalin in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes…
Very low06 Sep 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result…
Very low16 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Selank in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Feb 2025 -
Randomised, double-blind, placebo-controlled study of DSIP in sleep over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low14 May 2025 -
Randomised crossover, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low23 Feb 2025 -
Randomised, double-blind, placebo-controlled study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low31 Aug 2024 -
Phase 1 ascending dose, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Apr 2025 -
Phase 1 ascending dose, phase 1 study of Sermorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low02 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low04 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low05 Dec 2024 -
Randomised, double-blind, placebo-controlled study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Aug 2024 -
Randomised crossover, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low26 Jun 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low12 Sep 2024 -
Phase 1 ascending dose, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low01 Aug 2024 -
Randomised, double-blind, placebo-controlled study of Epithalon in ageing over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low01 Jun 2024
page 3 of 3